Medical expert of the article
New publications
Preparations
Olmesar
Last reviewed: 03.07.2025
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
Indications Olmesara
It is used for essential high blood pressure.
[ 3 ]
Release form
The release occurs in tablets, 7 pieces per blister. The box contains 1 or 4 blister packs.
Pharmacodynamics
The substance medoxomil olmesartan is a potent selective antagonist of angiotensin 2 conductors (form AT1). It slows down the influence of angiotensin 2, developing with the participation of AT1 conductors, regardless of the binding pathways and the source of angiotensin 2.
Selective antagonism of the above conductors increases plasma renin values, as well as angiotensin 1 and 2. At the same time, they slightly reduce the plasma aldosterone level. With elevated blood pressure, the drug promotes a long-term reduction in pressure (the effect depends on the portion size).
There is no information regarding a strong decrease in blood pressure when taking the first dose, and also regarding the development of tachyphylaxis due to prolonged use of the drug or withdrawal syndrome after stopping the drug. Taking a single dose of Olmesar per day leads to a gradual and effective decrease in blood pressure. This effect lasts for 24 hours.
Pharmacokinetics
Olmesar is a prodrug. The active component is rapidly converted into the medicinally active breakdown product olmesartan. This occurs during absorption of the drug from the gastrointestinal tract - under the influence of esterases, which are located in the portal blood and intestinal mucosa. No undegraded active component or unchanged side chain of the medoxomal category is found in the plasma or excretion products.
The average absolute bioavailability of the substance when taking a tablet is 25.6%. At the same time, the average maximum level of the active component in the plasma is observed after 2 hours after use. Plasma values of the drug increase in linear accordance with the increase in a single oral dose of the drug to 80 mg. Food intake has almost no effect on the bioavailability of the drug.
The synthesis of the drug with proteins inside the plasma reaches 99.7%, although it should be taken into account that it has a low potential for a noticeable shift in the level of protein synthesis for the therapeutic process in the case of combination with other drugs that have high protein binding rates. This fact is confirmed by the absence of significant drug interactions of Olmesar with warfarin or medoxomil.
[ 4 ]
Dosing and administration
The dose sizes of the medicine, as well as the duration of therapy, are determined only by the attending physician, individually for each patient.
It is necessary to take the tablets at the same time, regardless of food intake - breakfast time is suitable for taking.
The recommended starting dose of Olmesar is 10 mg, taken once a day. If the desired effect is not achieved, the dosage can be increased to the optimal daily dose, which is 20 mg.
If there is a need for additional reduction in blood pressure values, it is allowed to increase the dosage to the maximum daily limit (it is equal to 40 mg) or use a combination with hydrochlorothiazide.
The maximum hypotensive effect is observed after 2 months from the start of the course, although a noticeable decrease in blood pressure is noted after 2 weeks of therapy.
In case of renal dysfunction.
Individuals with moderate renal impairment (with a creatinine clearance level of 20-60 ml/minute) are required to take the drug at a dosage of 20 mg once a day.
People with severe renal impairment (with CC values <20 ml/minute) are prohibited from taking this medicine.
In case of liver dysfunction.
For people with moderate liver dysfunction, the starting dose is 10 mg once a day, and the maximum daily dose is 20 mg.
[ 7 ]
Use Olmesara during pregnancy
It is prohibited to prescribe the drug to pregnant or nursing mothers.
Contraindications
Main contraindications:
- intolerance to the components of the drug;
- obstruction affecting the biliary system;
- age category under 18 years.
Side effects Olmesara
The use of the drug may cause the appearance of certain side effects:
- reactions of the cardiovascular system: orthostatic hypotension occasionally occurs or a decrease in blood pressure values is observed. Angina pectoris is observed sporadically;
- damage to the hematopoietic system: thrombocytopenia occurs occasionally;
- dysfunction of the nervous system: headaches or dizziness are observed occasionally;
- problems with the respiratory system: pharyngitis, bronchitis or runny nose often appear. Cough occurs occasionally;
- Gastrointestinal disorders: gastroenteritis, diarrhea or dyspeptic symptoms are often observed. Vomiting, abdominal pain or nausea appear sporadically;
- lesions of the subcutaneous layer or skin surface: occasional rashes, itching, allergic dermatitis, swelling of the face, Quincke's edema or urticaria;
- musculoskeletal disorders: back pain, arthritis or skeletal pain often occur. Myalgia or muscle cramps may occasionally occur;
- symptoms affecting the urinary system: urinary tract infections or hematuria often occur. Acute renal failure occurs occasionally;
- systemic lesions: chest pain, flu-like symptoms and peripheral edema are often observed. A feeling of general malaise, as well as drowsiness or fatigue, develops occasionally;
- Laboratory test results: hypertriglyceridemia or hyperuricemia often appear, and the level of CPK increases. Hyperkalemia is occasionally observed. Liver enzyme levels, as well as blood urea and creatinine values, increase occasionally.
Overdose
The probability of intoxication with the drug is quite low. The most probable complication is an excessive decrease in blood pressure.
Treatment procedures are supportive and symptomatic – it is necessary to increase the blood pressure to the required values. There is no information on the excretion of the drug by dialysis.
Interactions with other drugs
Use in combination with other antihypertensive drugs may potentiate the effects of Olmesar.
As a result of the combination of the drug with NSAIDs, its hypotensive effect may decrease and the risk of developing acute renal failure may appear.
When treating with the simultaneous use of antacids (aluminum or magnesium hydroxide), the bioavailability of the drug decreases.
The pharmacokinetic parameters of the drug do not change when combined with digoxin or warfarin.
It is prohibited to combine the drug with lithium medications, because in this case the toxic properties of the latter are potentiated.
Due to the high risk of developing hyperkalemia, Olmesar should not be used simultaneously with potassium-sparing diuretics, potassium-containing drugs, or other drugs that can increase serum potassium levels (such drugs include heparin).
Storage conditions
Olmesar must be kept in a place out of reach of children. Temperature values - no higher than 25°C.
Shelf life
Olmesar can be used for 2 years from the date of manufacture of the drug.
Attention!
To simplify the perception of information, this instruction for use of the drug "Olmesar" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.
Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.